Effectiveness of BNT162b2 and CoronaVac COVID-19 vaccination against asymptomatic and symptomatic infection of SARS-CoV-2 omicron BA.2 in Hong Kong: a prospective cohort study
COVID-19 vaccines provide protection against symptomatic infection that might require medical attention and against severe outcomes; however, there is a paucity of evidence regarding the effectiveness of the BNT162b2 and CoronaVac vaccines and their booster regimens against asymptomatic or mild omic...
Saved in:
Published in | The Lancet infectious diseases Vol. 23; no. 4; pp. 421 - 434 |
---|---|
Main Authors | , , , , |
Format | Journal Article |
Language | English |
Published |
United States
Elsevier Ltd
01.04.2023
Elsevier Limited |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | COVID-19 vaccines provide protection against symptomatic infection that might require medical attention and against severe outcomes; however, there is a paucity of evidence regarding the effectiveness of the BNT162b2 and CoronaVac vaccines and their booster regimens against asymptomatic or mild omicron infections in the community. We aimed to measure the effectiveness of BNT162b2 and CoronaVac vaccines against asymptomatic and symptomatic SARS-CoV-2 omicron infections, during a period of omicron BA.2 predominance in Hong Kong.
In this prospective cohort study in a population that was generally infection-naive before the large omicron BA.2 wave between January and late May, 2022, we established a public health surveillance platform to monitor the evolving activity of SARS-CoV-2 infections in the community. We recruited a cohort of individuals aged 5 years and older between March 1 and March 7, 2022, from the general population. Individuals were enrolled from all 18 districts of Hong Kong, according to a predefined age-stratified quota, primarily by random digit dialing (generating suitable eight-digit local telephone numbers by randomly picking sets of the first four digits from a sampling frame, and randomly generating the last four digits), and supplemented by our existing cohorts (which included cohorts for studying influenza vaccination from school-based vaccination programmes and cohorts for SARS-CoV-2 seroprevalence from the community), to ensure representativeness of the population in Hong Kong. Participants did weekly rapid antigen testing with a self-collected pooled nasal and throat swab, regardless of symptom and exposure status, from March 1 to April 15, 2022. Individuals reporting a history of SARS-CoV-2 infection confirmed by laboratory PCR testing before enrolment were excluded from the vaccine effectiveness analysis to avoid potential bias due to infection-induced immunity. The primary outcomes of the study were the incidence of SARS-CoV-2 infection, including asymptomatic and symptomatic infections, and the vaccine effectiveness of BNT162b2 and CoronaVac vaccines. The effectiveness of one, two, and three doses of vaccination was estimated with a Cox proportional hazards regression model with time-dependent covariates, allowing for changes in vaccination status over time, after adjustment for demographic factors and pre-existing medical conditions.
Of the 8636 individuals included in the analysis, 7233 (84%) received at least two doses of vaccine, 3993 (46%) received booster doses, and 903 (10%) reported SARS-CoV-2 infection. Among these infections 589 (65·2%) were symptomatic and 314 (34·8%) were asymptomatic at the time of testing. Statistically significant protection against asymptomatic and symptomatic SARS-CoV-2 omicron infection was found only for those who received a BNT162b2 or CoronaVac booster dose, with a vaccine effectiveness of 41·4% (23·2 to 55·2; p=0·0001) and 32·4% (9·0 to 49·8; p=0·0098), respectively. The vaccine effectiveness of BNT162b2 and CoronaVac boosters was further increased to 50·9% (95% CI 31·0–65·0; p<0·0001) and 41·6% (15·0–59·8; p=0·0049), respectively, for symptomatic omicron infections. A similar pattern of vaccine effectiveness (55·8%, 22·9–74·6; p=0·0040) was also conferred after receipt of a BNT162b2 booster by individuals who received a CoronaVac primary vaccination series.
Two doses of either vaccine did not provide significant protection against COVID-19 infection. However, receipt of a BNT162b2 booster or CoronaVac booster was associated with a significantly lower risk of omicron BA.2 infection and symptomatic infection. Our findings confirm the effectiveness of booster doses to protect against mild and asymptomatic infection.
Henry Fok Foundation and Hong Kong Health Bureau. |
---|---|
AbstractList | Summary Background COVID-19 vaccines provide protection against symptomatic infection that might require medical attention and against severe outcomes; however, there is a paucity of evidence regarding the effectiveness of the BNT162b2 and CoronaVac vaccines and their booster regimens against asymptomatic or mild omicron infections in the community. We aimed to measure the effectiveness of BNT162b2 and CoronaVac vaccines against asymptomatic and symptomatic SARS-CoV-2 omicron infections, during a period of omicron BA.2 predominance in Hong Kong. Methods In this prospective cohort study in a population that was generally infection-naive before the large omicron BA.2 wave between January and late May, 2022, we established a public health surveillance platform to monitor the evolving activity of SARS-CoV-2 infections in the community. We recruited a cohort of individuals aged 5 years and older between March 1 and March 7, 2022, from the general population. Individuals were enrolled from all 18 districts of Hong Kong, according to a predefined age-stratified quota, primarily by random digit dialing (generating suitable eight-digit local telephone numbers by randomly picking sets of the first four digits from a sampling frame, and randomly generating the last four digits), and supplemented by our existing cohorts (which included cohorts for studying influenza vaccination from school-based vaccination programmes and cohorts for SARS-CoV-2 seroprevalence from the community), to ensure representativeness of the population in Hong Kong. Participants did weekly rapid antigen testing with a self-collected pooled nasal and throat swab, regardless of symptom and exposure status, from March 1 to April 15, 2022. Individuals reporting a history of SARS-CoV-2 infection confirmed by laboratory PCR testing before enrolment were excluded from the vaccine effectiveness analysis to avoid potential bias due to infection-induced immunity. The primary outcomes of the study were the incidence of SARS-CoV-2 infection, including asymptomatic and symptomatic infections, and the vaccine effectiveness of BNT162b2 and CoronaVac vaccines. The effectiveness of one, two, and three doses of vaccination was estimated with a Cox proportional hazards regression model with time-dependent covariates, allowing for changes in vaccination status over time, after adjustment for demographic factors and pre-existing medical conditions. Findings Of the 8636 individuals included in the analysis, 7233 (84%) received at least two doses of vaccine, 3993 (46%) received booster doses, and 903 (10%) reported SARS-CoV-2 infection. Among these infections 589 (65·2%) were symptomatic and 314 (34·8%) were asymptomatic at the time of testing. Statistically significant protection against asymptomatic and symptomatic SARS-CoV-2 omicron infection was found only for those who received a BNT162b2 or CoronaVac booster dose, with a vaccine effectiveness of 41·4% (23·2 to 55·2; p=0·0001) and 32·4% (9·0 to 49·8; p=0·0098), respectively. The vaccine effectiveness of BNT162b2 and CoronaVac boosters was further increased to 50·9% (95% CI 31·0–65·0; p<0·0001) and 41·6% (15·0–59·8; p=0·0049), respectively, for symptomatic omicron infections. A similar pattern of vaccine effectiveness (55·8%, 22·9–74·6; p=0·0040) was also conferred after receipt of a BNT162b2 booster by individuals who received a CoronaVac primary vaccination series. Interpretation Two doses of either vaccine did not provide significant protection against COVID-19 infection. However, receipt of a BNT162b2 booster or CoronaVac booster was associated with a significantly lower risk of omicron BA.2 infection and symptomatic infection. Our findings confirm the effectiveness of booster doses to protect against mild and asymptomatic infection. Funding Henry Fok Foundation and Hong Kong Health Bureau. COVID-19 vaccines provide protection against symptomatic infection that might require medical attention and against severe outcomes; however, there is a paucity of evidence regarding the effectiveness of the BNT162b2 and CoronaVac vaccines and their booster regimens against asymptomatic or mild omicron infections in the community. We aimed to measure the effectiveness of BNT162b2 and CoronaVac vaccines against asymptomatic and symptomatic SARS-CoV-2 omicron infections, during a period of omicron BA.2 predominance in Hong Kong. In this prospective cohort study in a population that was generally infection-naive before the large omicron BA.2 wave between January and late May, 2022, we established a public health surveillance platform to monitor the evolving activity of SARS-CoV-2 infections in the community. We recruited a cohort of individuals aged 5 years and older between March 1 and March 7, 2022, from the general population. Individuals were enrolled from all 18 districts of Hong Kong, according to a predefined age-stratified quota, primarily by random digit dialing (generating suitable eight-digit local telephone numbers by randomly picking sets of the first four digits from a sampling frame, and randomly generating the last four digits), and supplemented by our existing cohorts (which included cohorts for studying influenza vaccination from school-based vaccination programmes and cohorts for SARS-CoV-2 seroprevalence from the community), to ensure representativeness of the population in Hong Kong. Participants did weekly rapid antigen testing with a self-collected pooled nasal and throat swab, regardless of symptom and exposure status, from March 1 to April 15, 2022. Individuals reporting a history of SARS-CoV-2 infection confirmed by laboratory PCR testing before enrolment were excluded from the vaccine effectiveness analysis to avoid potential bias due to infection-induced immunity. The primary outcomes of the study were the incidence of SARS-CoV-2 infection, including asymptomatic and symptomatic infections, and the vaccine effectiveness of BNT162b2 and CoronaVac vaccines. The effectiveness of one, two, and three doses of vaccination was estimated with a Cox proportional hazards regression model with time-dependent covariates, allowing for changes in vaccination status over time, after adjustment for demographic factors and pre-existing medical conditions. Of the 8636 individuals included in the analysis, 7233 (84%) received at least two doses of vaccine, 3993 (46%) received booster doses, and 903 (10%) reported SARS-CoV-2 infection. Among these infections 589 (65·2%) were symptomatic and 314 (34·8%) were asymptomatic at the time of testing. Statistically significant protection against asymptomatic and symptomatic SARS-CoV-2 omicron infection was found only for those who received a BNT162b2 or CoronaVac booster dose, with a vaccine effectiveness of 41·4% (23·2 to 55·2; p=0·0001) and 32·4% (9·0 to 49·8; p=0·0098), respectively. The vaccine effectiveness of BNT162b2 and CoronaVac boosters was further increased to 50·9% (95% CI 31·0-65·0; p<0·0001) and 41·6% (15·0-59·8; p=0·0049), respectively, for symptomatic omicron infections. A similar pattern of vaccine effectiveness (55·8%, 22·9-74·6; p=0·0040) was also conferred after receipt of a BNT162b2 booster by individuals who received a CoronaVac primary vaccination series. Two doses of either vaccine did not provide significant protection against COVID-19 infection. However, receipt of a BNT162b2 booster or CoronaVac booster was associated with a significantly lower risk of omicron BA.2 infection and symptomatic infection. Our findings confirm the effectiveness of booster doses to protect against mild and asymptomatic infection. Henry Fok Foundation and Hong Kong Health Bureau. BACKGROUNDCOVID-19 vaccines provide protection against symptomatic infection that might require medical attention and against severe outcomes; however, there is a paucity of evidence regarding the effectiveness of the BNT162b2 and CoronaVac vaccines and their booster regimens against asymptomatic or mild omicron infections in the community. We aimed to measure the effectiveness of BNT162b2 and CoronaVac vaccines against asymptomatic and symptomatic SARS-CoV-2 omicron infections, during a period of omicron BA.2 predominance in Hong Kong. METHODSIn this prospective cohort study in a population that was generally infection-naive before the large omicron BA.2 wave between January and late May, 2022, we established a public health surveillance platform to monitor the evolving activity of SARS-CoV-2 infections in the community. We recruited a cohort of individuals aged 5 years and older between March 1 and March 7, 2022, from the general population. Individuals were enrolled from all 18 districts of Hong Kong, according to a predefined age-stratified quota, primarily by random digit dialing (generating suitable eight-digit local telephone numbers by randomly picking sets of the first four digits from a sampling frame, and randomly generating the last four digits), and supplemented by our existing cohorts (which included cohorts for studying influenza vaccination from school-based vaccination programmes and cohorts for SARS-CoV-2 seroprevalence from the community), to ensure representativeness of the population in Hong Kong. Participants did weekly rapid antigen testing with a self-collected pooled nasal and throat swab, regardless of symptom and exposure status, from March 1 to April 15, 2022. Individuals reporting a history of SARS-CoV-2 infection confirmed by laboratory PCR testing before enrolment were excluded from the vaccine effectiveness analysis to avoid potential bias due to infection-induced immunity. The primary outcomes of the study were the incidence of SARS-CoV-2 infection, including asymptomatic and symptomatic infections, and the vaccine effectiveness of BNT162b2 and CoronaVac vaccines. The effectiveness of one, two, and three doses of vaccination was estimated with a Cox proportional hazards regression model with time-dependent covariates, allowing for changes in vaccination status over time, after adjustment for demographic factors and pre-existing medical conditions. FINDINGSOf the 8636 individuals included in the analysis, 7233 (84%) received at least two doses of vaccine, 3993 (46%) received booster doses, and 903 (10%) reported SARS-CoV-2 infection. Among these infections 589 (65·2%) were symptomatic and 314 (34·8%) were asymptomatic at the time of testing. Statistically significant protection against asymptomatic and symptomatic SARS-CoV-2 omicron infection was found only for those who received a BNT162b2 or CoronaVac booster dose, with a vaccine effectiveness of 41·4% (23·2 to 55·2; p=0·0001) and 32·4% (9·0 to 49·8; p=0·0098), respectively. The vaccine effectiveness of BNT162b2 and CoronaVac boosters was further increased to 50·9% (95% CI 31·0-65·0; p<0·0001) and 41·6% (15·0-59·8; p=0·0049), respectively, for symptomatic omicron infections. A similar pattern of vaccine effectiveness (55·8%, 22·9-74·6; p=0·0040) was also conferred after receipt of a BNT162b2 booster by individuals who received a CoronaVac primary vaccination series. INTERPRETATIONTwo doses of either vaccine did not provide significant protection against COVID-19 infection. However, receipt of a BNT162b2 booster or CoronaVac booster was associated with a significantly lower risk of omicron BA.2 infection and symptomatic infection. Our findings confirm the effectiveness of booster doses to protect against mild and asymptomatic infection. FUNDINGHenry Fok Foundation and Hong Kong Health Bureau. |
Author | Cowling, Benjamin J Leung, Gabriel M So, Hau Chi Tsang, Nicole Ngai Yung Ip, Dennis Kai Ming |
Author_xml | – sequence: 1 givenname: Nicole Ngai Yung surname: Tsang fullname: Tsang, Nicole Ngai Yung organization: WHO Collaborating Centre for Infectious Disease Epidemiology and Control, School of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong Special Administrative Region, China – sequence: 2 givenname: Hau Chi surname: So fullname: So, Hau Chi organization: WHO Collaborating Centre for Infectious Disease Epidemiology and Control, School of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong Special Administrative Region, China – sequence: 3 givenname: Benjamin J surname: Cowling fullname: Cowling, Benjamin J organization: WHO Collaborating Centre for Infectious Disease Epidemiology and Control, School of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong Special Administrative Region, China – sequence: 4 givenname: Gabriel M surname: Leung fullname: Leung, Gabriel M organization: WHO Collaborating Centre for Infectious Disease Epidemiology and Control, School of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong Special Administrative Region, China – sequence: 5 givenname: Dennis Kai Ming surname: Ip fullname: Ip, Dennis Kai Ming email: dkmip@hku.hk organization: WHO Collaborating Centre for Infectious Disease Epidemiology and Control, School of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong Special Administrative Region, China |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/36521506$$D View this record in MEDLINE/PubMed |
BookMark | eNqFkktv1DAQxyNURB_wEUCWuJRDip9xwqFoGwqtqKjElr1aju1sXW3sYCcr7afiK-ImpSpc8MGP8W_-M2PPYbbnvDNZ9hrBEwRR8X6JKCc5gVV1jPE7CDnBOXyWHSQzzSllfG_az8h-dhjjHYSII0hfZPukYBgxWBxkv87b1qjBbo0zMQLfgrNvN6jADQbSaVD74J1cSQXq69XlpxxVYCuVsk4O1jsg19K6OAAZd10_-C5Z1eT39GzdFCHhSX25-L7Ma7_KMfCdVUkdnC1OcILAhXdr8DVNH4AEffCxnxMDyt_6MIA4jHr3Mnveyk00rx7Wo-zH5_Ob-iK_uv5yWS-uckUrNuRlKWHVNrwwkOGWpMJLSiCtClk2WnHMOCFMsooWLdUatYVBmjSaQQQbxFpNjrLTWbcfm85oZdwQ5Eb0wXYy7ISXVvx94-ytWPutqDhNAyeB4weB4H-OJg6is1GZzUY648coMGcsZVFiktC3_6B3fgwulZeosuKQ8IInis1UerQYg2kfk0FQ3LeEmFpC3P-3wFhMLSFg8nvztJJHrz89kICPM2DSe26tCSIqa5wy2ob0A0J7-58QvwHWCcfK |
CitedBy_id | crossref_primary_10_2174_1872208317666230612141930 crossref_primary_10_1016_j_eclinm_2023_102148 crossref_primary_10_1016_S1473_3099_23_00007_5 crossref_primary_10_1016_j_cell_2023_08_033 crossref_primary_10_1002_cbin_12130 crossref_primary_10_1002_acn3_52081 crossref_primary_10_1038_d41591_023_00084_w crossref_primary_10_1016_j_vaccine_2023_06_017 crossref_primary_10_1016_S2666_5247_23_00216_1 crossref_primary_10_1016_j_apm_2024_05_018 crossref_primary_10_1016_j_ijid_2024_107149 crossref_primary_10_1038_s41591_023_02212_y crossref_primary_10_1093_qjmed_hcae093 crossref_primary_10_1038_s41467_024_46104_2 crossref_primary_10_1016_j_chom_2023_05_017 crossref_primary_10_1038_s41392_023_01631_0 crossref_primary_10_1080_07853890_2024_2307504 crossref_primary_10_1038_s41467_024_47905_1 crossref_primary_10_1080_14787210_2024_2351571 crossref_primary_10_1186_s12931_023_02542_y crossref_primary_10_2807_1560_7917_ES_2024_29_13_2300403 crossref_primary_10_1080_21645515_2024_2361500 crossref_primary_10_1007_s10456_023_09878_5 crossref_primary_10_1016_j_cmi_2023_08_014 crossref_primary_10_1016_S2213_2600_23_00263_1 crossref_primary_10_3389_fmicb_2024_1384991 crossref_primary_10_1016_j_buildenv_2024_111491 crossref_primary_10_1016_j_eng_2024_01_016 crossref_primary_10_3201_eid3003_230893 |
Cites_doi | 10.1056/NEJMoa2203209 10.1056/NEJMoa2200797 10.1016/S2666-7568(22)00035-6 10.1128/Spectrum.00342-21 10.1080/22221751.2022.2106899 10.1136/oem.52.8.557 10.1001/jamanetworkopen.2021.32923 10.3201/eid2806.220158 10.1016/j.vaccine.2021.05.099 10.1056/NEJMoa2115481 10.1038/s41467-022-30895-3 10.1056/NEJMoa2117128 10.1016/j.cct.2022.106700 10.1001/jama.2022.7493 10.1016/S1473-3099(22)00409-1 10.1016/S1473-3099(22)00141-4 10.1016/S1473-3099(22)00309-7 10.1038/s41591-022-01816-0 10.1126/sciadv.abd5393 10.1093/infdis/jiab619 10.1001/jamanetworkopen.2022.9317 10.1080/21645515.2022.2045857 10.1016/S1473-3099(22)00345-0 10.1016/j.vaccine.2022.04.005 10.1001/jamanetworkopen.2022.13606 10.1056/NEJMoa2203965 10.1056/NEJMoa2119451 10.1002/sim.7019 10.15585/mmwr.mm7112e1 10.1111/irv.12993 10.1016/S2213-2600(21)00542-7 |
ContentType | Journal Article |
Copyright | 2023 Elsevier Ltd Copyright © 2023 Elsevier Ltd. All rights reserved. 2023. Elsevier Ltd 2022 Elsevier Ltd. All rights reserved. 2022 Elsevier Ltd |
Copyright_xml | – notice: 2023 Elsevier Ltd – notice: Copyright © 2023 Elsevier Ltd. All rights reserved. – notice: 2023. Elsevier Ltd – notice: 2022 Elsevier Ltd. All rights reserved. 2022 Elsevier Ltd |
DBID | CGR CUY CVF ECM EIF NPM AAYXX CITATION 0TZ 3V. 7QL 7RV 7U9 7X7 7XB 88E 8AO 8C1 8C2 8FI 8FJ 8FK ABUWG AFKRA BENPR C1K CCPQU FYUFA GHDGH H94 K9. KB0 M0S M1P M7N NAPCQ PQEST PQQKQ PQUKI 7X8 5PM |
DOI | 10.1016/S1473-3099(22)00732-0 |
DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef Pharma and Biotech Premium PRO ProQuest Central (Corporate) Bacteriology Abstracts (Microbiology B) Nursing & Allied Health Database (ProQuest) Virology and AIDS Abstracts Health & Medical Collection (Proquest) ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) ProQuest Pharma Collection Public Health Database (Proquest) Lancet Titles Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central AUTh Library subscriptions: ProQuest Central Environmental Sciences and Pollution Management ProQuest One Community College Health Research Premium Collection Health Research Premium Collection (Alumni) AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Database (Alumni Edition) Health & Medical Collection (Alumni Edition) PML(ProQuest Medical Library) Algology Mycology and Protozoology Abstracts (Microbiology C) Nursing & Allied Health Premium ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition MEDLINE - Academic PubMed Central (Full Participant titles) |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef Pharma and Biotech Premium PRO Lancet Titles ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest Pharma Collection Environmental Sciences and Pollution Management ProQuest Central Health Research Premium Collection Health and Medicine Complete (Alumni Edition) Bacteriology Abstracts (Microbiology B) Algology Mycology and Protozoology Abstracts (Microbiology C) AIDS and Cancer Research Abstracts ProQuest Medical Library (Alumni) ProQuest Public Health Virology and AIDS Abstracts ProQuest One Academic Eastern Edition ProQuest Nursing & Allied Health Source ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Hospital Collection (Alumni) Nursing & Allied Health Premium ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition ProQuest Nursing & Allied Health Source (Alumni) ProQuest One Academic ProQuest Central (Alumni) MEDLINE - Academic |
DatabaseTitleList | Pharma and Biotech Premium PRO MEDLINE MEDLINE - Academic |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 3 dbid: BENPR name: AUTh Library subscriptions: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine Public Health |
EISSN | 1474-4457 |
EndPage | 434 |
ExternalDocumentID | 10_1016_S1473_3099_22_00732_0 36521506 S1473309922007320 |
Genre | Research Support, Non-U.S. Gov't Journal Article |
GeographicLocations | Hong Kong Hong Kong China United States--US China |
GeographicLocations_xml | – name: Hong Kong – name: Hong Kong China – name: China – name: United States--US |
GrantInformation | Henry Fok Foundation and Hong Kong Health Bureau. |
GroupedDBID | --- --K --M -RU ..I .1- .FO 0R~ 123 1B1 1P~ 1~5 29L 3V. 4.4 457 4G. 53G 5VS 6PF 7-5 71M 7RV 7X7 88E 8AO 8C1 8C2 8FI 8FJ AAAJQ AACTN AAEDT AAEDW AAIKJ AAKOC AALRI AAQFI AAQQT AAQXK AARKO AAWTL AAXUO AAYOK ABBQC ABJNI ABLVK ABMAC ABMZM ABUWG ABYKQ ACGFS ACPRK ACRLP ADBBV ADMUD AEKER AENEX AEVXI AFKRA AFKWA AFRAH AFRHN AFTJW AFXIZ AGEKW AGHFR AHMBA AITUG AJBFU AJOXV AJRQY AJUYK ALMA_UNASSIGNED_HOLDINGS AMFUW AMRAJ ANZVX ASPBG AVWKF AXJTR AZFZN BENPR BKEYQ BKOJK BNPGV BPHCQ BVXVI CCPQU CJTIS CS3 DU5 EBS EFJIC EJD EO8 EO9 EP2 EP3 EX3 F5P FDB FEDTE FGOYB FIRID FNPLU FYGXN FYUFA G-Q GBLVA HF~ HMCUK HVGLF HZ~ IHE J1W KOM M1P M41 MO0 N9A NAPCQ O-L O9- OD- OO. OZT P-8 P-9 P2P PQQKQ PROAC PSQYO R2- RIG ROL RPZ SDF SDG SEL SES SPCBC SSH SSI SSZ T5K TLN UKHRP UV1 WOW XBR Z5R ZA5 AAMRU AAXKI AFCTW AKRWK ALIPV CGR CUY CVF ECM EIF NPM AAYXX CITATION 0TZ 7QL 7U9 7XB 8FK C1K H94 K9. M7N PQEST PQUKI 7X8 5PM |
ID | FETCH-LOGICAL-c495t-88a09fb76e052f30178430496a8bdc7257335a5946f4dd1f6e1d3bd5010b15fd3 |
IEDL.DBID | 8C1 |
ISSN | 1473-3099 |
IngestDate | Tue Sep 17 21:30:49 EDT 2024 Sat Oct 05 04:39:05 EDT 2024 Thu Oct 03 06:30:59 EDT 2024 Thu Sep 26 19:20:45 EDT 2024 Sat Sep 28 08:12:42 EDT 2024 Fri Feb 23 02:37:21 EST 2024 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 4 |
Language | English |
License | Copyright © 2023 Elsevier Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c495t-88a09fb76e052f30178430496a8bdc7257335a5946f4dd1f6e1d3bd5010b15fd3 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
OpenAccessLink | https://pubmed.ncbi.nlm.nih.gov/PMC9744442 |
PMID | 36521506 |
PQID | 2789703767 |
PQPubID | 44001 |
PageCount | 14 |
ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_9744442 proquest_miscellaneous_2755573823 proquest_journals_2789703767 crossref_primary_10_1016_S1473_3099_22_00732_0 pubmed_primary_36521506 elsevier_sciencedirect_doi_10_1016_S1473_3099_22_00732_0 |
PublicationCentury | 2000 |
PublicationDate | 2023-04-01 |
PublicationDateYYYYMMDD | 2023-04-01 |
PublicationDate_xml | – month: 04 year: 2023 text: 2023-04-01 day: 01 |
PublicationDecade | 2020 |
PublicationPlace | United States |
PublicationPlace_xml | – name: United States – name: London |
PublicationTitle | The Lancet infectious diseases |
PublicationTitleAlternate | Lancet Infect Dis |
PublicationYear | 2023 |
Publisher | Elsevier Ltd Elsevier Limited |
Publisher_xml | – name: Elsevier Ltd – name: Elsevier Limited |
References | Altarawneh, Chemaitelly, Ayoub (bib4) 2022; 387 Mi, Hammill, Curtis, Lai, Setoguchi (bib25) 2016; 35 Jensen, Stromme, Moyassari (bib23) 2022; 115 Lauring, Tenforde, Chappell (bib2) 2022; 376 (bib29) June 7, 2022 Higdon, Baidya, Walter (bib37) 2022; 22 Kuitunen, Uimonen, Seppälä, Ponkilainen (bib10) 2022; 16 Madewell, Yang, Longini, Halloran, Dean (bib44) 2022; 5 Chemaitelly, Ayoub, AlMukdad (bib39) 2022; 13 Chen, Abdullah, Chan (bib27) 2022; 13 (bib32) May 20, 2022 (bib54) 2022 (bib30) May 2, 2022 Jung, Kim, Park (bib41) 2022; 5 Lewis, Naioti, Self (bib24) 2022; 225 Emani, Pallipuram, Goswami (bib33) 2022 Tenforde, Self, Gaglani (bib40) 2022; 71 Tan, Cook, Heng, Ong, Lye, Tan (bib12) 2022; 387 Glasziou, McCaffery, Cvejic (bib11) 2022; 7 Puhach, Adea, Hulo (bib42) 2022; 28 Wacholder, Hartge, Lubin, Dosemeci (bib52) 1995; 52 Baum, Poukka, Leino, Kilpi, Nohynek, Palmu (bib6) 2022 (bib50) Dec 7, 2021 Linkins, Iorio, Little, Lavis (bib13) 2022; 40 Andrews, Tessier, Stowe (bib22) 2022; 386 (bib15) Sept 28, 2020 (bib49) Dec 16, 2021 Poon, Chan, Chan (bib28) 2022; 11 (bib16) March 16, 2022 Andrews, Stowe, Kirsebom (bib8) 2022; 386 Boon, Wong, Ng (bib14) 2021; 4 Zee, Chan, Leung (bib17) 2022; 28 Ewald (bib43) 1994 Lyngse, Kirkeby, Denwood (bib47) 2022 Patel, Bergeri, Bresee (bib26) 2021; 39 Dinnes, Sharma, Berhane (bib51) 2022; 7 (bib31) May 26, 2022 Del Águila-Mejía, Wallmann, Calvo-Montes, Rodríguez-Lozano, Valle-Madrazo, Aginagalde-Llorente (bib45) 2022; 28 Ranzani, Hitchings, Dorion (bib36) 2021; 374 Sheikh, Kerr, Woolhouse (bib5) 2022; 22 Fleming-Dutra, Britton, Shang (bib9) 2022; 327 Cohen (bib19) 1988 Chiu, Kojima, Mosley (bib18) 2021; 9 Stowe, Andrews, Kirsebom, Ramsay, Bernal (bib38) 2022 Kirsebom, Andrews, Stowe (bib7) 2022; 22 Tan, Kwan, Rodríguez-Barraquer (bib46) 2022 (bib48) May 21, 2022 Arregocés-Castillo, Fernández-Niño, Rojas-Botero (bib34) 2022; 3 Abu-Raddad, Chemaitelly, Ayoub (bib1) 2022; 386 Chadeau-Hyam, Wang, Eales (bib21) 2022; 10 Nanishi, Levy, Ozonoff (bib35) 2022; 18 Lin, Gu, Wheeler (bib20) 2022; 386 McMenamin, Nealon, Lin (bib3) 2022; 22 Larremore, Wilder, Lester (bib53) 2021; 7 Chen (10.1016/S1473-3099(22)00732-0_bib27) 2022; 13 Puhach (10.1016/S1473-3099(22)00732-0_bib42) 2022; 28 Kuitunen (10.1016/S1473-3099(22)00732-0_bib10) 2022; 16 Tenforde (10.1016/S1473-3099(22)00732-0_bib40) 2022; 71 Kirsebom (10.1016/S1473-3099(22)00732-0_bib7) 2022; 22 Glasziou (10.1016/S1473-3099(22)00732-0_bib11) 2022; 7 Boon (10.1016/S1473-3099(22)00732-0_bib14) 2021; 4 Nanishi (10.1016/S1473-3099(22)00732-0_bib35) 2022; 18 Baum (10.1016/S1473-3099(22)00732-0_bib6) 2022 Lewis (10.1016/S1473-3099(22)00732-0_bib24) 2022; 225 Ranzani (10.1016/S1473-3099(22)00732-0_bib36) 2021; 374 Stowe (10.1016/S1473-3099(22)00732-0_bib38) 2022 Chemaitelly (10.1016/S1473-3099(22)00732-0_bib39) 2022; 13 Zee (10.1016/S1473-3099(22)00732-0_bib17) 2022; 28 Chadeau-Hyam (10.1016/S1473-3099(22)00732-0_bib21) 2022; 10 Cohen (10.1016/S1473-3099(22)00732-0_bib19) 1988 Jung (10.1016/S1473-3099(22)00732-0_bib41) 2022; 5 Higdon (10.1016/S1473-3099(22)00732-0_bib37) 2022; 22 Chiu (10.1016/S1473-3099(22)00732-0_bib18) 2021; 9 Wacholder (10.1016/S1473-3099(22)00732-0_bib52) 1995; 52 Tan (10.1016/S1473-3099(22)00732-0_bib12) 2022; 387 Linkins (10.1016/S1473-3099(22)00732-0_bib13) 2022; 40 Lin (10.1016/S1473-3099(22)00732-0_bib20) 2022; 386 Ewald (10.1016/S1473-3099(22)00732-0_bib43) 1994 Sheikh (10.1016/S1473-3099(22)00732-0_bib5) 2022; 22 Altarawneh (10.1016/S1473-3099(22)00732-0_bib4) 2022; 387 Patel (10.1016/S1473-3099(22)00732-0_bib26) 2021; 39 Fleming-Dutra (10.1016/S1473-3099(22)00732-0_bib9) 2022; 327 Tan (10.1016/S1473-3099(22)00732-0_bib46) 2022 Lauring (10.1016/S1473-3099(22)00732-0_bib2) 2022; 376 McMenamin (10.1016/S1473-3099(22)00732-0_bib3) 2022; 22 Emani (10.1016/S1473-3099(22)00732-0_bib33) 2022 Del Águila-Mejía (10.1016/S1473-3099(22)00732-0_bib45) 2022; 28 Mi (10.1016/S1473-3099(22)00732-0_bib25) 2016; 35 Jensen (10.1016/S1473-3099(22)00732-0_bib23) 2022; 115 Dinnes (10.1016/S1473-3099(22)00732-0_bib51) 2022; 7 Andrews (10.1016/S1473-3099(22)00732-0_bib22) 2022; 386 Madewell (10.1016/S1473-3099(22)00732-0_bib44) 2022; 5 Abu-Raddad (10.1016/S1473-3099(22)00732-0_bib1) 2022; 386 Andrews (10.1016/S1473-3099(22)00732-0_bib8) 2022; 386 Arregocés-Castillo (10.1016/S1473-3099(22)00732-0_bib34) 2022; 3 Larremore (10.1016/S1473-3099(22)00732-0_bib53) 2021; 7 Poon (10.1016/S1473-3099(22)00732-0_bib28) 2022; 11 Lyngse (10.1016/S1473-3099(22)00732-0_bib47) 2022 |
References_xml | – volume: 387 start-page: 525 year: 2022 end-page: 532 ident: bib12 article-title: Effectiveness of BNT162b2 vaccine against omicron in children 5 to 11 years of age publication-title: N Engl J Med contributor: fullname: Tan – volume: 374 year: 2021 ident: bib36 article-title: Effectiveness of the CoronaVac vaccine in older adults during a gamma variant associated epidemic of COVID-19 in Brazil: test negative case-control study publication-title: BMJ contributor: fullname: Dorion – year: June 7, 2022 ident: bib29 article-title: COVID-19 vaccination programme – volume: 386 start-page: 1532 year: 2022 end-page: 1546 ident: bib8 article-title: Covid-19 vaccine effectiveness against the omicron (B.1.1.529) variant publication-title: N Engl J Med contributor: fullname: Kirsebom – volume: 16 start-page: 842 year: 2022 end-page: 845 ident: bib10 article-title: COVID-19 vaccination status and testing rates in Finland—a potential cause for bias in observational vaccine effectiveness analysis publication-title: Influenza Other Respir Viruses contributor: fullname: Ponkilainen – volume: 5 year: 2022 ident: bib41 article-title: Transmission and infectious SARS-CoV-2 shedding kinetics in vaccinated and unvaccinated individuals publication-title: JAMA Network Open contributor: fullname: Park – volume: 28 start-page: 300 year: 2022 end-page: 305 ident: bib17 article-title: Rapid antigen test during a COVID-19 outbreak in a private hospital in Hong Kong publication-title: Hong Kong Med J contributor: fullname: Leung – volume: 28 start-page: 1491 year: 2022 end-page: 1500 ident: bib42 article-title: Infectious viral load in unvaccinated and vaccinated individuals infected with ancestral, delta or omicron SARS-CoV-2 publication-title: Nat Med contributor: fullname: Hulo – year: 2022 ident: bib38 article-title: Effectiveness of COVID-19 vaccines against omicron and delta hospitalisation: test negative case-control study publication-title: medRxiv contributor: fullname: Bernal – volume: 22 start-page: 931 year: 2022 end-page: 933 ident: bib7 article-title: COVID-19 vaccine effectiveness against the omicron (BA.2) variant in England publication-title: Lancet Infect Dis contributor: fullname: Stowe – year: March 16, 2022 ident: bib16 article-title: INDICAID COVID-19 rapid antigen at-home test – volume: 9 year: 2021 ident: bib18 article-title: Evaluation of the INDICAID COVID-19 rapid antigen test in symptomatic populations and asymptomatic community testing publication-title: Microbiol Spectr contributor: fullname: Mosley – volume: 386 start-page: 340 year: 2022 end-page: 350 ident: bib22 article-title: Duration of protection against mild and severe disease by COVID-19 vaccines publication-title: N Engl J Med contributor: fullname: Stowe – volume: 225 start-page: 1694 year: 2022 end-page: 1700 ident: bib24 article-title: Effectiveness of mRNA vaccines against COVID-19 hospitalization by age and chronic medical conditions burden among immunocompetent US adults, March–August, 2021 publication-title: J Infect Dis contributor: fullname: Self – year: May 2, 2022 ident: bib30 article-title: COVID-19 vaccine booster recommendations – year: May 21, 2022 ident: bib48 article-title: Recommendation for additional dose(s) of COVID-19 vaccination – volume: 13 year: 2022 ident: bib27 article-title: Contribution of low population immunity to the severe omicron BA.2 outbreak in Hong Kong publication-title: Nat Commun contributor: fullname: Chan – volume: 40 start-page: 2986 year: 2022 end-page: 2987 ident: bib13 article-title: Extended reporting guidance for vaccine effectiveness studies for variants of concern for COVID-19 publication-title: Vaccine contributor: fullname: Lavis – year: Sept 28, 2020 ident: bib15 article-title: COVID-19 target product profiles for priority diagnostics to support response to the COVID-19 pandemic v.1.0 – volume: 7 year: 2021 ident: bib53 article-title: Test sensitivity is secondary to frequency and turnaround time for COVID-19 screening publication-title: Sci Adv contributor: fullname: Lester – volume: 39 start-page: 4013 year: 2021 end-page: 4024 ident: bib26 article-title: Evaluation of post-introduction COVID-19 vaccine effectiveness: summary of interim guidance of the World Health Organization publication-title: Vaccine contributor: fullname: Bresee – volume: 386 start-page: 933 year: 2022 end-page: 941 ident: bib20 article-title: Effectiveness of COVID-19 vaccines over a 9-month period in North Carolina publication-title: N Engl J Med contributor: fullname: Wheeler – year: Dec 7, 2021 ident: bib50 article-title: EMA and ECDC recommendations on heterologous vaccination courses against COVID-19: ‘mix-and-match’ approach can be used for both initial courses and boosters – volume: 387 start-page: 21 year: 2022 end-page: 34 ident: bib4 article-title: Effects of previous infection and vaccination on symptomatic omicron infections publication-title: N Engl J Med contributor: fullname: Ayoub – volume: 386 start-page: 1804 year: 2022 end-page: 1816 ident: bib1 article-title: Effect of mRNA vaccine boosters against SARS-CoV-2 omicron infection in Qatar publication-title: N Engl J Med contributor: fullname: Ayoub – volume: 71 start-page: 459 year: 2022 end-page: 465 ident: bib40 article-title: Effectiveness of mRNA vaccination in preventing COVID-19-associated invasive mechanical ventilation and death—United States, March 2021–January 2022 publication-title: MMWR Morb Mortal Wkly Rep contributor: fullname: Gaglani – year: May 26, 2022 ident: bib31 article-title: Clinical recommendations for COVID-19 vaccines – volume: 4 year: 2021 ident: bib14 article-title: Seroprevalence of unidentified SARS-CoV-2 infection in Hong Kong during 3 pandemic waves publication-title: JAMA Netw Open contributor: fullname: Ng – volume: 115 year: 2022 ident: bib23 article-title: COVID-19 vaccines: considering sex differences in efficacy and safety publication-title: Contemp Clin Trials contributor: fullname: Moyassari – volume: 3 start-page: e242 year: 2022 end-page: e252 ident: bib34 article-title: Effectiveness of COVID-19 vaccines in older adults in Colombia: a retrospective, population-based study of the ESPERANZA cohort publication-title: Lancet Healthy Longev contributor: fullname: Rojas-Botero – volume: 22 start-page: 1435 year: 2022 end-page: 1443 ident: bib3 article-title: Vaccine effectiveness of one, two, and three doses of BNT162b2 and CoronaVac against COVID-19 in Hong Kong: a population-based observational study publication-title: Lancet Infect Dis contributor: fullname: Lin – volume: 11 start-page: 2116 year: 2022 end-page: 2119 ident: bib28 article-title: SARS-CoV-2 IgG seropositivity after the severe omicron wave of COVID-19 in Hong Kong publication-title: Emerg Microbes Infect contributor: fullname: Chan – volume: 22 start-page: 959 year: 2022 end-page: 966 ident: bib5 article-title: Severity of omicron variant of concern and effectiveness of vaccine boosters against symptomatic disease in Scotland (EAVE II): a national cohort study with nested test-negative design publication-title: Lancet Infect Dis contributor: fullname: Woolhouse – volume: 5 year: 2022 ident: bib44 article-title: Household secondary attack rates of SARS-CoV-2 by variant and vaccination status: an updated systematic review and meta-analysis publication-title: JAMA Network Open contributor: fullname: Dean – volume: 327 start-page: 2210 year: 2022 end-page: 2219 ident: bib9 article-title: Association of prior BNT162b2 COVID-19 vaccination with symptomatic SARS-CoV-2 infection in children and adolescents during omicron predominance publication-title: JAMA contributor: fullname: Shang – year: 2022 ident: bib46 article-title: Infectiousness of SARS-CoV-2 breakthrough infections and reinfections during the Omicron wave publication-title: medRxiv contributor: fullname: Rodríguez-Barraquer – volume: 28 start-page: 1224 year: 2022 end-page: 1228 ident: bib45 article-title: Secondary attack rate, transmission and incubation periods, and serial interval of SARS-CoV-2 omicron variant, Spain publication-title: Emerg Infect Dis contributor: fullname: Aginagalde-Llorente – year: 1994 ident: bib43 article-title: Evolution of infectious disease contributor: fullname: Ewald – volume: 52 start-page: 557 year: 1995 end-page: 558 ident: bib52 article-title: Non-differential misclassification and bias towards the null: a clarification publication-title: Occup Environ Med contributor: fullname: Dosemeci – year: 1988 ident: bib19 article-title: Statistical power analysis for the behavioral sciences contributor: fullname: Cohen – volume: 10 start-page: 355 year: 2022 end-page: 366 ident: bib21 article-title: SARS-CoV-2 infection and vaccine effectiveness in England (REACT-1): a series of cross-sectional random community surveys publication-title: Lancet Respir Med contributor: fullname: Eales – year: 2022 ident: bib47 article-title: Transmission of SARS-CoV-2 omicron VOC subvariants BA.1 and BA.2: evidence from Danish households publication-title: medRxiv contributor: fullname: Denwood – volume: 18 year: 2022 ident: bib35 article-title: Waning effectiveness of SARS-CoV-2 mRNA vaccines in older adults: a rapid review publication-title: Hum Vaccin Immunother contributor: fullname: Ozonoff – volume: 7 year: 2022 ident: bib51 article-title: Rapid, point-of-care antigen tests for diagnosis of SARS-CoV-2 infection publication-title: Cochrane Database Syst Rev contributor: fullname: Berhane – volume: 22 start-page: 1114 year: 2022 end-page: 1116 ident: bib37 article-title: Duration of effectiveness of vaccination against COVID-19 caused by the omicron variant publication-title: Lancet Infect Dis contributor: fullname: Walter – volume: 13 year: 2022 ident: bib39 article-title: Duration of mRNA vaccine protection against SARS-CoV-2 omicron BA.1 and BA.2 subvariants in Qatar publication-title: Nat Commun contributor: fullname: AlMukdad – volume: 376 year: 2022 ident: bib2 article-title: Clinical severity of, and effectiveness of mRNA vaccines against, COVID-19 from omicron, delta, and alpha SARS-CoV-2 variants in the United States: prospective observational study publication-title: BMJ contributor: fullname: Chappell – volume: 35 start-page: 4824 year: 2016 end-page: 4836 ident: bib25 article-title: Use of the landmark method to address immortal person-time bias in comparative effectiveness research: a simulation study publication-title: Stat Med contributor: fullname: Setoguchi – year: 2022 ident: bib6 article-title: High vaccine effectiveness against severe COVID-19 in the elderly in Finland before and after the emergence of omicron publication-title: medRxiv contributor: fullname: Palmu – year: 2022 ident: bib54 article-title: Prevention and control of disease ordinance (cap 599) – volume: 7 start-page: 242 year: 2022 end-page: 246 ident: bib11 article-title: Testing behaviour may bias observational studies of vaccine effectiveness publication-title: JAMMI contributor: fullname: Cvejic – year: Dec 16, 2021 ident: bib49 article-title: Interim recommendations for heterologous COVID-19 vaccine schedules – year: May 20, 2022 ident: bib32 article-title: Interim clinical considerations for use of COVID-19 vaccines currently approved or authorized in the United States – year: 2022 ident: bib33 article-title: Increasing SARS-CoV2 cases, hospitalizations and deaths among the vaccinated elderly populations during the omicron (B.1.1.529) variant surge in UK publication-title: medRxiv contributor: fullname: Goswami – volume: 387 start-page: 525 year: 2022 ident: 10.1016/S1473-3099(22)00732-0_bib12 article-title: Effectiveness of BNT162b2 vaccine against omicron in children 5 to 11 years of age publication-title: N Engl J Med doi: 10.1056/NEJMoa2203209 contributor: fullname: Tan – volume: 386 start-page: 1804 year: 2022 ident: 10.1016/S1473-3099(22)00732-0_bib1 article-title: Effect of mRNA vaccine boosters against SARS-CoV-2 omicron infection in Qatar publication-title: N Engl J Med doi: 10.1056/NEJMoa2200797 contributor: fullname: Abu-Raddad – volume: 3 start-page: e242 year: 2022 ident: 10.1016/S1473-3099(22)00732-0_bib34 article-title: Effectiveness of COVID-19 vaccines in older adults in Colombia: a retrospective, population-based study of the ESPERANZA cohort publication-title: Lancet Healthy Longev doi: 10.1016/S2666-7568(22)00035-6 contributor: fullname: Arregocés-Castillo – volume: 9 year: 2021 ident: 10.1016/S1473-3099(22)00732-0_bib18 article-title: Evaluation of the INDICAID COVID-19 rapid antigen test in symptomatic populations and asymptomatic community testing publication-title: Microbiol Spectr doi: 10.1128/Spectrum.00342-21 contributor: fullname: Chiu – volume: 376 year: 2022 ident: 10.1016/S1473-3099(22)00732-0_bib2 article-title: Clinical severity of, and effectiveness of mRNA vaccines against, COVID-19 from omicron, delta, and alpha SARS-CoV-2 variants in the United States: prospective observational study publication-title: BMJ contributor: fullname: Lauring – volume: 11 start-page: 2116 year: 2022 ident: 10.1016/S1473-3099(22)00732-0_bib28 article-title: SARS-CoV-2 IgG seropositivity after the severe omicron wave of COVID-19 in Hong Kong publication-title: Emerg Microbes Infect doi: 10.1080/22221751.2022.2106899 contributor: fullname: Poon – volume: 52 start-page: 557 year: 1995 ident: 10.1016/S1473-3099(22)00732-0_bib52 article-title: Non-differential misclassification and bias towards the null: a clarification publication-title: Occup Environ Med doi: 10.1136/oem.52.8.557 contributor: fullname: Wacholder – volume: 4 year: 2021 ident: 10.1016/S1473-3099(22)00732-0_bib14 article-title: Seroprevalence of unidentified SARS-CoV-2 infection in Hong Kong during 3 pandemic waves publication-title: JAMA Netw Open doi: 10.1001/jamanetworkopen.2021.32923 contributor: fullname: Boon – volume: 28 start-page: 1224 year: 2022 ident: 10.1016/S1473-3099(22)00732-0_bib45 article-title: Secondary attack rate, transmission and incubation periods, and serial interval of SARS-CoV-2 omicron variant, Spain publication-title: Emerg Infect Dis doi: 10.3201/eid2806.220158 contributor: fullname: Del Águila-Mejía – volume: 39 start-page: 4013 year: 2021 ident: 10.1016/S1473-3099(22)00732-0_bib26 article-title: Evaluation of post-introduction COVID-19 vaccine effectiveness: summary of interim guidance of the World Health Organization publication-title: Vaccine doi: 10.1016/j.vaccine.2021.05.099 contributor: fullname: Patel – volume: 386 start-page: 340 year: 2022 ident: 10.1016/S1473-3099(22)00732-0_bib22 article-title: Duration of protection against mild and severe disease by COVID-19 vaccines publication-title: N Engl J Med doi: 10.1056/NEJMoa2115481 contributor: fullname: Andrews – volume: 13 year: 2022 ident: 10.1016/S1473-3099(22)00732-0_bib39 article-title: Duration of mRNA vaccine protection against SARS-CoV-2 omicron BA.1 and BA.2 subvariants in Qatar publication-title: Nat Commun doi: 10.1038/s41467-022-30895-3 contributor: fullname: Chemaitelly – volume: 386 start-page: 933 year: 2022 ident: 10.1016/S1473-3099(22)00732-0_bib20 article-title: Effectiveness of COVID-19 vaccines over a 9-month period in North Carolina publication-title: N Engl J Med doi: 10.1056/NEJMoa2117128 contributor: fullname: Lin – volume: 115 year: 2022 ident: 10.1016/S1473-3099(22)00732-0_bib23 article-title: COVID-19 vaccines: considering sex differences in efficacy and safety publication-title: Contemp Clin Trials doi: 10.1016/j.cct.2022.106700 contributor: fullname: Jensen – year: 1994 ident: 10.1016/S1473-3099(22)00732-0_bib43 contributor: fullname: Ewald – volume: 327 start-page: 2210 year: 2022 ident: 10.1016/S1473-3099(22)00732-0_bib9 article-title: Association of prior BNT162b2 COVID-19 vaccination with symptomatic SARS-CoV-2 infection in children and adolescents during omicron predominance publication-title: JAMA doi: 10.1001/jama.2022.7493 contributor: fullname: Fleming-Dutra – year: 2022 ident: 10.1016/S1473-3099(22)00732-0_bib38 article-title: Effectiveness of COVID-19 vaccines against omicron and delta hospitalisation: test negative case-control study publication-title: medRxiv contributor: fullname: Stowe – volume: 22 start-page: 1114 year: 2022 ident: 10.1016/S1473-3099(22)00732-0_bib37 article-title: Duration of effectiveness of vaccination against COVID-19 caused by the omicron variant publication-title: Lancet Infect Dis doi: 10.1016/S1473-3099(22)00409-1 contributor: fullname: Higdon – volume: 22 start-page: 959 year: 2022 ident: 10.1016/S1473-3099(22)00732-0_bib5 article-title: Severity of omicron variant of concern and effectiveness of vaccine boosters against symptomatic disease in Scotland (EAVE II): a national cohort study with nested test-negative design publication-title: Lancet Infect Dis doi: 10.1016/S1473-3099(22)00141-4 contributor: fullname: Sheikh – volume: 22 start-page: 931 year: 2022 ident: 10.1016/S1473-3099(22)00732-0_bib7 article-title: COVID-19 vaccine effectiveness against the omicron (BA.2) variant in England publication-title: Lancet Infect Dis doi: 10.1016/S1473-3099(22)00309-7 contributor: fullname: Kirsebom – volume: 28 start-page: 1491 year: 2022 ident: 10.1016/S1473-3099(22)00732-0_bib42 article-title: Infectious viral load in unvaccinated and vaccinated individuals infected with ancestral, delta or omicron SARS-CoV-2 publication-title: Nat Med doi: 10.1038/s41591-022-01816-0 contributor: fullname: Puhach – volume: 7 year: 2021 ident: 10.1016/S1473-3099(22)00732-0_bib53 article-title: Test sensitivity is secondary to frequency and turnaround time for COVID-19 screening publication-title: Sci Adv doi: 10.1126/sciadv.abd5393 contributor: fullname: Larremore – volume: 225 start-page: 1694 year: 2022 ident: 10.1016/S1473-3099(22)00732-0_bib24 article-title: Effectiveness of mRNA vaccines against COVID-19 hospitalization by age and chronic medical conditions burden among immunocompetent US adults, March–August, 2021 publication-title: J Infect Dis doi: 10.1093/infdis/jiab619 contributor: fullname: Lewis – year: 2022 ident: 10.1016/S1473-3099(22)00732-0_bib33 article-title: Increasing SARS-CoV2 cases, hospitalizations and deaths among the vaccinated elderly populations during the omicron (B.1.1.529) variant surge in UK publication-title: medRxiv contributor: fullname: Emani – year: 2022 ident: 10.1016/S1473-3099(22)00732-0_bib47 article-title: Transmission of SARS-CoV-2 omicron VOC subvariants BA.1 and BA.2: evidence from Danish households publication-title: medRxiv contributor: fullname: Lyngse – volume: 7 year: 2022 ident: 10.1016/S1473-3099(22)00732-0_bib51 article-title: Rapid, point-of-care antigen tests for diagnosis of SARS-CoV-2 infection publication-title: Cochrane Database Syst Rev contributor: fullname: Dinnes – volume: 28 start-page: 300 year: 2022 ident: 10.1016/S1473-3099(22)00732-0_bib17 article-title: Rapid antigen test during a COVID-19 outbreak in a private hospital in Hong Kong publication-title: Hong Kong Med J contributor: fullname: Zee – year: 2022 ident: 10.1016/S1473-3099(22)00732-0_bib6 article-title: High vaccine effectiveness against severe COVID-19 in the elderly in Finland before and after the emergence of omicron publication-title: medRxiv contributor: fullname: Baum – volume: 5 year: 2022 ident: 10.1016/S1473-3099(22)00732-0_bib44 article-title: Household secondary attack rates of SARS-CoV-2 by variant and vaccination status: an updated systematic review and meta-analysis publication-title: JAMA Network Open doi: 10.1001/jamanetworkopen.2022.9317 contributor: fullname: Madewell – volume: 18 year: 2022 ident: 10.1016/S1473-3099(22)00732-0_bib35 article-title: Waning effectiveness of SARS-CoV-2 mRNA vaccines in older adults: a rapid review publication-title: Hum Vaccin Immunother doi: 10.1080/21645515.2022.2045857 contributor: fullname: Nanishi – volume: 22 start-page: 1435 year: 2022 ident: 10.1016/S1473-3099(22)00732-0_bib3 article-title: Vaccine effectiveness of one, two, and three doses of BNT162b2 and CoronaVac against COVID-19 in Hong Kong: a population-based observational study publication-title: Lancet Infect Dis doi: 10.1016/S1473-3099(22)00345-0 contributor: fullname: McMenamin – year: 2022 ident: 10.1016/S1473-3099(22)00732-0_bib46 article-title: Infectiousness of SARS-CoV-2 breakthrough infections and reinfections during the Omicron wave publication-title: medRxiv contributor: fullname: Tan – volume: 40 start-page: 2986 year: 2022 ident: 10.1016/S1473-3099(22)00732-0_bib13 article-title: Extended reporting guidance for vaccine effectiveness studies for variants of concern for COVID-19 publication-title: Vaccine doi: 10.1016/j.vaccine.2022.04.005 contributor: fullname: Linkins – volume: 13 year: 2022 ident: 10.1016/S1473-3099(22)00732-0_bib27 article-title: Contribution of low population immunity to the severe omicron BA.2 outbreak in Hong Kong publication-title: Nat Commun contributor: fullname: Chen – volume: 5 year: 2022 ident: 10.1016/S1473-3099(22)00732-0_bib41 article-title: Transmission and infectious SARS-CoV-2 shedding kinetics in vaccinated and unvaccinated individuals publication-title: JAMA Network Open doi: 10.1001/jamanetworkopen.2022.13606 contributor: fullname: Jung – volume: 387 start-page: 21 year: 2022 ident: 10.1016/S1473-3099(22)00732-0_bib4 article-title: Effects of previous infection and vaccination on symptomatic omicron infections publication-title: N Engl J Med doi: 10.1056/NEJMoa2203965 contributor: fullname: Altarawneh – volume: 386 start-page: 1532 year: 2022 ident: 10.1016/S1473-3099(22)00732-0_bib8 article-title: Covid-19 vaccine effectiveness against the omicron (B.1.1.529) variant publication-title: N Engl J Med doi: 10.1056/NEJMoa2119451 contributor: fullname: Andrews – volume: 35 start-page: 4824 year: 2016 ident: 10.1016/S1473-3099(22)00732-0_bib25 article-title: Use of the landmark method to address immortal person-time bias in comparative effectiveness research: a simulation study publication-title: Stat Med doi: 10.1002/sim.7019 contributor: fullname: Mi – volume: 71 start-page: 459 year: 2022 ident: 10.1016/S1473-3099(22)00732-0_bib40 article-title: Effectiveness of mRNA vaccination in preventing COVID-19-associated invasive mechanical ventilation and death—United States, March 2021–January 2022 publication-title: MMWR Morb Mortal Wkly Rep doi: 10.15585/mmwr.mm7112e1 contributor: fullname: Tenforde – volume: 7 start-page: 242 year: 2022 ident: 10.1016/S1473-3099(22)00732-0_bib11 article-title: Testing behaviour may bias observational studies of vaccine effectiveness publication-title: JAMMI contributor: fullname: Glasziou – volume: 374 year: 2021 ident: 10.1016/S1473-3099(22)00732-0_bib36 article-title: Effectiveness of the CoronaVac vaccine in older adults during a gamma variant associated epidemic of COVID-19 in Brazil: test negative case-control study publication-title: BMJ contributor: fullname: Ranzani – volume: 16 start-page: 842 year: 2022 ident: 10.1016/S1473-3099(22)00732-0_bib10 article-title: COVID-19 vaccination status and testing rates in Finland—a potential cause for bias in observational vaccine effectiveness analysis publication-title: Influenza Other Respir Viruses doi: 10.1111/irv.12993 contributor: fullname: Kuitunen – year: 1988 ident: 10.1016/S1473-3099(22)00732-0_bib19 contributor: fullname: Cohen – volume: 10 start-page: 355 year: 2022 ident: 10.1016/S1473-3099(22)00732-0_bib21 article-title: SARS-CoV-2 infection and vaccine effectiveness in England (REACT-1): a series of cross-sectional random community surveys publication-title: Lancet Respir Med doi: 10.1016/S2213-2600(21)00542-7 contributor: fullname: Chadeau-Hyam |
SSID | ssj0017104 |
Score | 2.5880842 |
Snippet | COVID-19 vaccines provide protection against symptomatic infection that might require medical attention and against severe outcomes; however, there is a... Summary Background COVID-19 vaccines provide protection against symptomatic infection that might require medical attention and against severe outcomes;... BACKGROUNDCOVID-19 vaccines provide protection against symptomatic infection that might require medical attention and against severe outcomes; however, there... |
SourceID | pubmedcentral proquest crossref pubmed elsevier |
SourceType | Open Access Repository Aggregation Database Index Database Publisher |
StartPage | 421 |
SubjectTerms | Antigens Asymptomatic Asymptomatic infection Autoantigens BNT162 Vaccine Cohort analysis Coronaviruses COVID-19 COVID-19 - epidemiology COVID-19 - prevention & control COVID-19 Vaccines Digits Disease transmission Drug dosages Effectiveness Effectiveness studies Hong Kong - epidemiology Humans Immunization Infections Infectious diseases Laboratories mRNA vaccines Pandemics Population Population studies Prospective Studies Public health Regression models SARS-CoV-2 Seroepidemiologic Studies Serology Severe acute respiratory syndrome coronavirus 2 Statistical analysis Surveillance Time dependence Vaccination Vaccine efficacy Vaccines |
Title | Effectiveness of BNT162b2 and CoronaVac COVID-19 vaccination against asymptomatic and symptomatic infection of SARS-CoV-2 omicron BA.2 in Hong Kong: a prospective cohort study |
URI | https://dx.doi.org/10.1016/S1473-3099(22)00732-0 https://www.ncbi.nlm.nih.gov/pubmed/36521506 https://www.proquest.com/docview/2789703767/abstract/ https://search.proquest.com/docview/2755573823 https://pubmed.ncbi.nlm.nih.gov/PMC9744442 |
Volume | 23 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwhV1Lb9QwEB71ISEkhKC8FsrKSBzg4G7sxE6WC9pdWi2suqDdtuwt8iMuPZAsbYrEr-IvMs6rLQjIIVES20o0Y_uzZ-YbgJfWc5pLi2sTZSVFSG1okomMhmYYGRlox4SPdz6cy-lx9GElVhswbWNhvFtlOyZWA7UtjN8jH_iITdTOWMYDpf0ugCkHb9ffqM8f5e2sTTKNTdhmqKI-iUMy6Zw9GM6jlX05ikMaIii6iuUZLLuHrzh_7S1XnAZ_m6X-RKG_O1Nem50O7sHdBlaSUa0H92Ejy3fg1mFjON-BO_X2HKmjjh7Az5q1uBnqSOHIeH7EJNecqNySiec1UCfKkMnHk_fvKBuS78pgU5UciTpVZwgribr48XVdFhXra1Xv-n3r5pX71pejxZJOihPKiQ-DxtbJeLTHsRCZFvkpmeHpDVEEf7yN_SQ-d-95SSoC3IdwfLB_NJnSJncDNbjkKmmSqGDodCyzQHCHo0icRN6iJ1WirYm5p2EUSgwj6SJrmZMZs6G2ApeHmglnw0ewlRd59gRIFgkWWmMQ7JnIsUxzbaVQXCqnnQtZD_ZaWaXrmqIj7XzXvHBTL9yU87QSbhr0IGklmjY4o8YPKU4j_6u622pA2nT2i_RKNXvwonuN3dTbXlSeFZe-jBD4zwkPe_C4VpjuY0OJGEoEsgfxDVXqCngK8Jtv8rMvFRU4rgbx4E___VnP4DZHbFY7HO3CVnl-mT1HLFXqPmzGq7hfdZY-bI9mi88zvI73558WvwD3qR5w |
link.rule.ids | 230,315,786,790,891,12083,12250,21416,27957,27958,31754,31755,33301,33302,33779,33780,43345,43614,43840,74102,74371,74659 |
linkProvider | ProQuest |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwhV1Lb9QwELagSICEEBRKAwWMxAEObmM7drJc0Hah2tLuIrHbVW-WH3HbA8nSTZH4VfxFxnm1BQE5REr8UKIZez57Zj4j9NoFTnPpYG2inSQAqS3JcpETbgeJlbHxVIR858lUjo-ST8fiuN1wW7Vhld2cWE_UrrRhj3wnZGyCdqYyfb_8RsKpUcG72h6hcRPdSjgYmpApPupDPChYz9qrnKSccIBClxk8O7P-5RvG3gZ_FSPx32zTn9jz9xDKKzZp7wG634JJPGyk_xDdyIt1dHvSusvX0b1mUw43uUaP0M-Gq7id4HDp8e50TiUzDOvC4VFgM9ALbfHo82L_A6ED_F1b6KqWHtYn-gzAJNarH1-XVVlzvdbtrj53wV1F6H02_DIjo3JBGA7Jz9A73h1uM6iEx2Vxgg_g9g5rDD_eZXzicGLveYVr2tvH6Gjv43w0Ju2JDcTCQqsiWabjgTepzGPBPMwdaZYEP57UmXE2ZYF8UWgxSKRPnKNe5tRx4wQsCg0V3vENtFaURb6JcJ4Iyp21APFs4mlumHFSaCa1N95zGqHtTlZq2RBzqD5iLQhXBeEqxlQtXBVHKOskqlp00aAGBcbjf023Og1Q7RBfqUuFjNCrvhgGZ_C46CIvL0IdIeCfM8Yj9KRRmP5juQTkJGIZofSaKvUVAvH39ZLi7LQmAIc1IFzs6b8_6yW6M55PDtXh_vTgGbrLAJ01IUdbaK06v8ifA5qqzIt6yPwCbN4Zgg |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwhV1bb9MwFLZgkyYkhGDcAgOMxAM8eE2c2El5QW23qmOsTOtW7c3ydeyBpKwdEr-Kv8hx4mQbCMhDpMQX2TrH9mefcz4j9MZ4TnNuYG8iDScAqTUpLLMk1f1M81i5hPl454Mpn5xkH0_ZafB_Wga3ynZOrCdqU2l_Rt7zEZugnTnPey64RRzujD8svhF_g5S3tIbrNG6j9TzjDDR8fbg7PTzqbAqwltY25ixPSQrA6Cqepzfrfr6l9J23XlES_22l-hOJ_u5QeW2FGt9H9wK0xINGFx6gW7bcRBsHwXi-ie42R3S4iTx6iH42zMVhusOVw8PpccKpoliWBo88t4GcS41Hn-d7OyTp4-9SQ1W1LLE8k-cALbFc_vi6WFU182td7vp36-pV-tpng6MZGVVzQrEPhYba8XCwTSETnlTlGd6H13ssMXS8jf_E_v7eixWuSXAfoZPx7vFoQsL9DUTDtmtFikLGfadybmNGHcwkeZF5qx6XhTI6p56KkUnWz7jLjEkct4lJlWGwRVQJcyZ9jNbKqrRPEbYZS1KjNQA-nbnEKqoMZ5Jy6ZRzaRKh7VZWYtHQdIjOf80LV3jhCkpFLVwRR6hoJSoC1mgwhICl5H9Ft1oNEGHAL8WVekbodZcMQ9XbX2Rpq0ufhzHoc0HTCD1pFKZrbMoBR7GYRyi_oUpdBk8DfjOlPP9S04HDjhAe-uzfzXqFNmC8iE970_3n6A4FqNb4H22htdXFpX0B0GqlXoYx8wsmCB9a |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Effectiveness+of+BNT162b2+and+CoronaVac+COVID-19+vaccination+against+asymptomatic+and+symptomatic+infection+of+SARS-CoV-2+omicron+BA.2+in+Hong+Kong%3A+a+prospective+cohort+study&rft.jtitle=The+Lancet+infectious+diseases&rft.au=Nicole+Ngai+Yung+Tsang&rft.au=So%2C+Hau+Chi&rft.au=Cowling%2C+Benjamin+J&rft.au=Leung%2C+Gabriel+M&rft.date=2023-04-01&rft.pub=Elsevier+Limited&rft.issn=1473-3099&rft.eissn=1474-4457&rft.volume=23&rft.issue=4&rft.spage=421&rft_id=info:doi/10.1016%2FS1473-3099%2822%2900732-0&rft.externalDBID=HAS_PDF_LINK |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1473-3099&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1473-3099&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1473-3099&client=summon |